Federation Des Caisses Desjardins Du Quebec Atea Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.4 Billion
Q4 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $74 - $109	24 New	24 $97,000
Q2 2022 Aug 14, 2024	SELL	$5.33 - $8.18 $3,731 - $5,726	-700 Closed	0 $0
Q1 2022 Aug 14, 2024	BUY	$5.5 - $9.19 $3,850 - $6,433	700 New	700 $5.05 Million
Q4 2021 Aug 30, 2024	BUY	$7.67 - $44.59 $5,369 - $31,213	700 New	700 $6.26 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

50.9M

Call Options Held

900

Put Options Held

63K

Black Rock Inc. New York, NY

9.12M
Shares

$28.7 Million
0.0% of portfolio
Bml Capital Management, LLC Zionsville, IN

7.61M
Shares

$24 Million
15.83% of portfolio
Tang Capital Management LLC San Diego, CA

4.79M
Shares

$15.1 Million
1.21% of portfolio
Vanguard Group Inc Valley Forge, PA

4.67M
Shares

$14.7 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

3.34M
Shares

$10.5 Million
0.52% of portfolio

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $262M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account